. Multicolor and 3-dimensional (D) imaging of the thrombi formed under arterial blood flow conditions. Type I collagen fibrils were perfused with blood containing fluoresceinated platelets for 8 min at a wall shear rate of 1,500 /s in a rectangular flow chamber. Thrombi formed on the collagen fibrils were visualized using both an epi-fluorescent multicolor video-microscope and the newly developed ultra-fast confocal laser microscope equipped with a piezo-motor control unit, as depicted schematically on the left-hand side. The activation of platelet-derived procoagulant activity was detected as the appearance of the fibrin monomer complex around the platelet thrombi visualized (in red), while platelets were visualized in green. The objective lens was moved up and down at a constant speed of 0.4 μm/s under the control of the piezo-motor control unit (a) to obtain scanning images of the platelet thrombi (a'). The sum of the scanning confocal images from the bottom to the top was projected on planes at 10-degree intervals relative to the x-axis to obtain the 3-D projection images shown on the right-hand side, including the projections at 0 degrees (top view, A), 60 degrees (B) and 90 degrees (front view, C). The maximum height (h) of the platelet thrombi was calculated from the frontal projection image, as shown in C. Platelet thrombi formed as a result of perfusion of the collagen fibrils with whole blood for 8 min (Left). Next, they were incubated with HEPESNaCl solution (pH 7.4) containing either 1 of the monoclonal antibodies, negative control antibody against thyroglobulin (Tγ), human fibrin monomer complex (F-405), or positive control antibody against the platelet surface protein GPIbα (GUR20-5) at a concentration of 5 μg/ml for 15 min. The specificity of the red fluorescence staining in the presence of antihuman fibrin monomer complex antibody (B) was confirmed by comparison with the staining results obtained with negative (A) and positive (C) control antibody. Superimposition of the green and red fluorescence staining images revealed the prominent presence of the fibrin monomer complex on the surface of the platelet thrombi.
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platelet thrombi, on calcium signaling, and on the growth of the platelet thrombi. [25] [26] [27] Clinically relevant anticoagulants, including unfractionated heparin and low-molecular-weight heparin, were also tested, but the results could not be included because the blood coagulated during experiments.
For the experiments conducted to examine the growth of the thrombi and imaging of the platelet-derived procoagulant activity, platelets in whole blood samples were rendered fluorescent by the addition of mepacrine (Sigma Chemical Co, St Louis, MO, USA). 25, 27, 28 For the experiments conducted to measure the intra-cytosolic calcium ion concentrations ([Ca 2+ ]i), the platelets were loaded with the calciumsensitive dye, fluo-3AM, in accordance with a previously described procedure, 29 with slight modification. 26 Fluo-3 loaded platelets were re-suspended in homologous, initially separated platelet-poor plasma containing the antithrombin agent argatroban at a concentration of 10 or 100 μmol/L. The hematocrit of the final cell suspension was adjusted to 40%.
A rectangular flow chamber with its glass bottom coated with immobilized type I collagen fibrils was assembled as described previously. 14, 25, 28 The experimental blood samples were aspirated into the chamber with a syringe pump (Harvard Apparatus, Holliston, MA, USA) for 8 min at a constant flow rate to obtain a wall shear rate of 1,500 /s unless otherwise specified (limited number of experiments were conducted at shear rate 0 and 100 /s).
Imaging of the Platelet Thrombi and Measurement of Platelet-Derived Procoagulant Activity
The platelet thrombi were initially visualized using an inverted-stage epi-fluorescence video-microscopy system connected to a 480-nm excitation light source (DM IRB, 1RB-FLUO, Leica, Germany). 14, 25 To quantify the 2-dimensional (D) growth of the platelet thrombi, both the surface area coverage of individual platelet thrombi (μm 2 ) and the total surface area coverage of the platelets (%) were calculated. 25 The 3-D projection images of the platelet thrombi were also obtained with a fast confocal laser microscope equipped with a piezo-motor control unit, as described previously 26, 30, 31 (Figure 1) . The 3-D projection images of the thrombi were obtained using the ImageJ 1.29v program (National Institutes of Health, Bethesda, MD, USA), as shown in Figure 1 . 26, 30, 31 The maximum height of the thrombi was calculated from a 90-degree (front) projection image, and the volume of each thrombus was derived by integration of the cumulative cross-sectional area occupied by the platelets in confocal sections obtained at 0.2-μm intervals. For imaging of the activation of the coagulation cascade on the surface of the platelet thrombi (platelet-derived procoagulant activity), HEPES-NaCl solution (pH 7.4) containing mouse-derived monoclonal antibody against the human fibrin monomer complex F-405 32 at a final concentration of 5 μg/ml was incubated with the platelet thrombi formed after 8 min of blood perfusion (Figure 1) . The presence of the anti-fibrin monomer complex antibody on the platelet thrombi was detected using Alexafluor594-conjugated goat-derived anti-mouse polyclonal IgG (Molecular Probes, Inc, OR, USA) at a final concentration of 10 μg/ml. Both FITC-conjugated Annexin V (kindly provided by Dr Nomura, Kansai University, Osaka, Japan) and Alexafluor594-conjugated monoclonal antibody against tissue factor ATN-8 (kindly provided by Chugai, Co Ltd, Gotenba, Japan) were used in some experiments to detect the distribution of negatively charged phospholipids and/or tissue factor on and/or around the platelet thrombi. 15, 33 Dualcolor fluorescence imaging, to detect platelets as green and the fibrin monomer complex as red, was performed after the washing procedure with a barrier filter centered at wavelengths of 527 nm and 600 nm, respectively (Figure 2) . The specificity of detection of the fibrin monomer complex by this method was confirmed by comparison with the same concentration of iso-type matched negative and positive control IgG (GUR20-5: antibody against platelet GPIbα, kindly provided by Dr Handa, Keio University, Tokyo, Japan) as shown in Figure 2 . Quantitative densitometry was performed to measure the total amount of fibrin monomer complex formed around the platelet thrombi using the same method as that described previously to estimate the amount of platelet accumulation. 27 
Real-Time Imaging to Measure [Ca 2+ ]i in Platelets Forming Thrombi Under Blood Flow Conditions
The [Ca 2+ ]i of the platelets forming thrombi was measured using the same confocal microscopy system described previously, 29, 26 but without the use of the piezo-motor control unit. Variations in the fluorescence intensity of the fluo-3AM-loaded platelets were converted into [Ca 2+ ]i using the equation: Relationship between functional inhibition of thrombin and the generation of the fibrin monomer complex around the platelet thrombi. The experiments were conducted in a similar manner as described in Figure 3 . Dual-color fluorescence imaging was performed after washing with secondary antibody 3 times with 5 ml of HEPES-NaCl solution (pH 7.4). Fluoresceinated platelets (green), and fibrin monomers (red) were visualized using a barrier filter centered at the wavelengths of 527 nm (A) and 600 nm (B), respectively. Quantitative densitometry was performed to detect the total amount of fibrin monomers formed around the platelet thrombi, and the results are summarized in the lower panel.
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where Kd is the dissociation constant of fluo-3AM in the interaction with Ca 2+ (corresponding to 495 nmol/L at 25°C), 34 F is the measured fluorescence intensity of a single platelet, Fmax is the fluorescence intensity of a single platelet treated with the Ca 2+ ionophore A23187 (10 μmol/L; Sigma) in the presence of 2 mmol/L calcium chloride, and Fmin is the fluorescence intensity of an unstimulated single platelet. To examine whether the changes in the [Ca 2+ ]i were related to trans-membrane entry or changes in the intracellular distribution, the effects of lanthanum chloride, a putative calciumchannel blocker, were tested. 26, 35 
Statistical Analysis
All numerical data are expressed as mean ± SD, unless otherwise specified. The effect of various concentrations of argatroban on the growth of the platelet thrombi was tested by 1-way analysis of variance (ANOVA). Differences between 2 groups of data were evaluated by Newman-Keuls test; P<0.05 was considered to denote statistical significance.
Results

Inter-Relationship Between Inhibition of the Coagulation Cascade and Growth of Platelet Thrombi
As shown in Figure 3 , the size of the individual thrombi that formed on the collagen fibrils was smaller after perfusion of blood containing higher concentrations of thrombin inhibitor. Quantitative analysis revealed that the area covered by individual platelet thrombi in the presence of thrombin inhibitor at concentrations of 50 and 100 μmol/L was significantly smaller than that formed in the presence of 10 μmol/L (P<0.05), as shown in Figure 3 and Table 1 . The total surface area covered by the platelets was not significantly influenced by the concentration of thrombin inhibitor, indicating that a larger number of smaller thrombi formed in the presence of higher concentrations of thrombin inhibitor.
The 3-D projection imaging of the platelet thrombi using our newly developed confocal imaging technique revealed that the height and volume of individual thrombi formed after 8 min of perfusion of blood containing lower concentrations of thrombin inhibitor were larger than those formed after perfusion of blood containing higher concentrations of the same inhibitor (Figure 3, Table 1 ).
Activation of the Coagulant Cascade Around Activated Platelets and the Role in Maintaining the Activated State of Platelets Incorporated Into Thrombi Under Arterial Blood Flow Conditions
As shown in the upper panels of Figure 4 , there was a larger amount of fibrin monomer complex, detected as red fluorescence, around the platelet thrombi formed in the presence of lower concentrations of thrombin inhibitor. A similar distribution of FITC-conjugated Annexin V could be detected under the same conditions, whereas neither tissue factor nor tissue-factor-bearing microparticles, a homogeneous distribution of which could be detected by our imaging system, were detected around the platelet thrombi (data not shown). Quantitative densitometric analysis, shown in the lower panel of Figure 4 , demonstrates the dosedependent inhibitory effects of thrombin inhibitor on the generation of the fibrin monomer complex around the platelet thrombi formed under arterial blood flow conditions. The [Ca 2+ ]i of the platelets adhering to the collagen fibrils is shown in Figure 5A . A cyclic increase in the [Ca 2+ ]i occurred in the majority of individual platelets adhering to the immobilized collagen fibrils, although the strength and cycle length of the oscillations were not homogeneous. The addition of the putative calcium-channel blocker, lanthanum chloride, at a final concentration of 1 mmol/L to the blood samples completely blocked these cyclic increases in the [Ca 2+ ]i 26 (data not shown). There was, however, a tendency for the maximum increase in the [Ca 2+ ]i to be greater in the presence of lower concentrations of thrombin inhibitor. Indeed, quantitative analysis of 20 randomly selected platelets in 4 different experiments revealed that both the maximum value and the differences between the maximum and minimum values of [Ca 2+ ]i were significantly higher in the presence of 10 μmol/L argatroban than the corresponding values in the presence of 100 μmol/L of the same inhibitor ( Figure 6A) . We also demonstrated that the cyclic increase in the [Ca 2+ ]i is shear rate dependent and disappears at a shear rate of 0 ( Figure 6B) .
Discussion
In the present study, we demonstrated activation of the coagulation cascade around platelet thrombi formed under arterial blood flow conditions, as evidenced by the appearance of fibrin monomer complexes around the platelet thrombi. We have also demonstrated that the cyclic increase in [Ca 2+ ]i in each platelet incorporated into the thrombi, which is assumed to represent the sum of the activation signals of the platelet and has been shown to be influenced by shear rate and the presence of specific thrombin inhibitor, positively correlates with the 3-D growth, especially in the z-section, of the platelet thrombi. Our experimental results suggest an important regulatory role of thrombin generated on the surface of activated platelets as a result of the procoagulant activity in both the formation of fibrin around the platelets and the maintenance of the activated state of platelets incorporated into thrombi so that the platelet thrombi remain stable and, at least in our experimental conditions, the calcium-sensitive phospholipid scramblase 36, 37 is activated to continue further expression of procoagulant phospholipid on the platelet thrombi (Figure 7) . 38, 39 Our experimental results with human blood samples were in complete agreement with in vivo animal experiments published previously. 33 Our findings fundamentally serve to confirm those animal experimental results, except that we used human blood in an in vitro setup without blood vessels. Obviously, our model does not pose any problems related to species differences, which is important in understanding the regulatory role of the activation of the coagulant cascade in the 3-D growth of platelet thrombi, because it is well known that the thrombin receptor, a major possible regulator in humans, is a different moiety in mice. Indeed, proteaseactivated receptor, 40 which is the most important functional receptor of thrombin in humans, is not expressed on mouse platelets. 23 Perhaps the main limitations of our blood perfusion model, however, are the differences in the blood flow conditions and the matrix exposed to the blood stream we used from an in vivo setting. Moreover, we had to use at least a minimal amount of anticoagulant to maintain blood fluidity during our experiments, which could influence the generation and function of thrombin. Our experiments cannot assess the clinically relevant, low dose of anticoagulant (not only argatroban, but also unfractionated heparin, low-molecular-weight heparin, etc). Moreover, our method is not applicable for assessing the effects of various antiplatelet agents on platelet-derived procoagulant activity because it requires the formation of large-enough platelet thrombi on collagen fibrils, which is inhibited by antiplatelet agents. Our methodology to detect fibrin monomer is not sensitive enough to detect small changes at various shear rates. We are attempting overcome this limitation by improving imaging tool, but could not provide relevant results in the current report.
Despite these limitations, the thrombi that formed on the collagen fibrils in our experimental model, and comprised both activated platelets and fibrin, were basically the same as the pathological arterial thrombi causing myocardial infarction, although the latter contain a larger amount of insoluble fibrin fibrils. 2,3 Nevertheless, we believe that our main findings give new insights into the key role of activated platelet-derived procoagulant activity in the growth of thrombi. We propose this begins with activation of the platelets accumulating at a site of endothelial injury under blood flow conditions, followed by the appearance of activatedplatelet-derived procoagulant activity 41 and the generation of thrombi on the membrane surface of activated platelets, even under arterial flow conditions, which results in both local fibrin fibril formation and in continuous activation of the platelets forming thrombi by repetitive stimulation of thrombin receptors, causing an increase in [Ca 2+ ]i to activate phospholipid scramblase 37 and further enhancing platelet-derived procoagulant activity, 42 as well as maintaining the stability of platelet thrombi for the development of large arterial occlusive thrombi (Figure 7) . 26 There is an interesting previous publication showing that mice that are deficient in phospholipid scramblase do not express bleeding problems. 36 In this context, regulation of phospholipid scramblase might be a possible target of antiplatelet agents with least bleeding complications. Further investigation is awaited.
Nonetheless, our experimental results provide little information regarding the mechanism of induction of the plateletderived procoagulant activity, the details of which are still to be clarified. 43, 44 Previous reports have demonstrated the importance of the surface expression of negatively charged phospholipids, mostly phosphatidylserine, 45 which can be detected by Annexin V binding, 15 and its appearance was confirmed in our study in association with activation of the coagulation cascade on the surface of the activated platelets. It is also known that increased [Ca 2+ ]i, which was shown in our study, especially in the presence of low concentrations of thrombin inhibitor (Figure 6 ), plays certain important roles in the activation of phospholipid scramblase, 26 resulting in surface exposure of phosphatidylserine. 46 Accordingly, our results showing an increase in the [Ca 2+ ]i of the platelet forming thrombi not only indicate the activated state of the platelets, but also the induction of procoagulant activity resulting in the appearance of the fibrin monomer complex. Indeed, a previous report demonstrated that factor IXa binding to platelet and generation of activated factor Xa was prevented by the putative Ca 2+ channel-blocker of lanthanum chloride. 47 Unlike in vivo animal experiments 33, 48 or atherothrombosis in humans, 2,3,6 our experiments did not include tissue factor originating from the vascular wall or ruptured atheroma. Thus, tissue factor, if it played a role in the generation of fibrin in our experiments, is limited to a blood-borne one. 48 The limitation to our experiments that a small amount of anticoagulant is required makes it impossible to assess whether the lower amount of fibrin fibril formation we observed is because of a lack of vessel-related tissue factor or represents the effects of antithrombin. The fact that we could detect neither soluble tissue factor nor accumulation of tissue-factor-bearing microparticles around the platelet thrombi in our experiments, despite the significant amount of tissue factor detected on the surface of the monocytes Figure 7 . Regulatory role of platelet-derived procoagulant activity on the continuous activation of platelet and thrombus growth. Platelets, once they interact with subendothelial matrix such as collagen or von Willebrand factor (VWF), 48, 49 activated to release ADP-containing dense granules. Next, the released ADP stimulates ADP receptors (P2Y1 and P2Y12). As previously demonstrated, continuous stimulation of P2Y12 results in a cyclic increase in [Ca 2+ ]i, which activates many Ca 2+ -dependent enzymes, such as phospholipid scramblase. Activation of that enzyme increased the expression of procoagulant negatively charged phospholipid, which supports conversion of prothrombin to thrombin on the surface of the activated platelet. Thrombin generated on the surface of activated platelets further activates the platelet through thrombin receptors.
that were eventually incorporated into the thrombi (data not shown), causes us to speculate that the role of tissue factor may not have been important in the initiation of the activation of the coagulation cascade around the platelet thrombi, at least in our flow chamber system. Nevertheless, some investigators have demonstrated the initiation of the coagulation cascade by phospholipids and Factor XI on erythrocytes, even in the absence of tissue factor, 49 which may be relevant to our present results. In any case, further investigations are required to elucidate the correct mechanism of the initiation of the activation of the coagulation cascade on the surface of the platelet thrombi under blood flow conditions.
In conclusion, in experiments using human blood under artificial blood flow conditions, we have demonstrated, using a 2-color imaging system, the local production of fibrin around the surface of activated platelets (activated plateletderived procoagulant activity) forming thrombi, even in the presence of specific antithrombin agents in the blood in amounts sufficient to maintain the fluidity of the blood during the experiments. We have shown a positive relationship between the magnitude of the increase in the [Ca 2+ ]i of the platelets incorporated within thrombi and the amount of fibrin monomer complex generated around them. We have also demonstrated the role of increased [Ca 2+ ]i of the platelets incorporated within the thrombi in maintaining the stability of the platelet thrombi and, consequently, their 3-D growth. The recognition of these functional links between the activation of the platelets and local activation of the coagulation cascade around them may provide new insight into the crucial role of platelet-derived procoagulant activity in the regulation of arterial thrombus growth. Our results suggest a regulatory role of both the activation of the coagulation cascade on the surface of platelet thrombi and the local generation of thrombin, even under arterial blood flow conditions, not only in the local generation of fibrin fibrils around platelet thrombi but also in maintaining the stability of platelet thrombi and further enhancing procoagulant activity related to the activation of phospholipid scramblase following an increase in the [Ca 2+ ]i of the platelets forming thrombi. We have thus shown a close functional linkage between the activation of platelets and the coagulation system even under arterial blood flow conditions.
